Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543115 | 0.77 | KDM4E (0.50) | CYP2A6TDP1CYP19A1 | |
| SCHEMBL2126189 | 0.70 | PDPK1 (0.45) | CYP2A6PDK1 | |
| SCHEMBL8087933 | 0.66 | CYP1A2 (0.44) | — | |
| SCHEMBL4507635 | 0.66 | MAPT (0.43) | CYP2A6 | |
| SCHEMBL117020 | 0.64 | CYP3A4 (0.41) | CYP2A6TDP1 | |
| SCHEMBL4031084 | 0.63 | IDO1 (0.38) | — | |
| SCHEMBL5757555 | 0.61 | PDK1 (0.30) | PDK1 | |
| SCHEMBL171853 | 0.61 | HDAC8 (0.47) | CYP2A6TDP1 | |
| SCHEMBL467198 | 0.60 | KDM4E (0.35) | CYP2A6TDP1 | |
| SCHEMBL1198354 | 0.60 | CYP2A6 (0.37) | CYP2A6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016154075-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-09-29 | — | — | WO | claimed |
| EP-1646638-A2 | 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2006-04-19 | — | — | EP | claimed |
| WO-2004108746-A2 | 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| WO-2004108745-A2 | 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| US-6774115-B1 | BACTERICIDES | ENANTA PHARMACEUTICALS, INC. | 2004-08-10 | — | — | US | claimed |
| EP-0432275-B1 | SUBSTITUTED BICYCLOHEPTANDIONE DERIVATIVES | NIPPON SODA CO (JP) | 1995-03-01 | — | — | EP | claimed |
| US-4695567-A | Pyrrolobenzimidazoles, pharmaceutical compositions containing them and method of using them to treat certain heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1987-09-22 | — | — | US | claimed |
| US-11345689-B2 | Compound and organic light emitting display device | Shanghai Tianma AM-OLED Co., Ltd. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20180370957-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DISPLAY DEVICE | Shanghai Tianma AM-OLED Co., Ltd (CN) | 2018-12-27 | — | — | US | disclosed |
| WO-2016154075-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-09-29 | — | — | WO | disclosed |
| EP-2509602-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | Cylene Pharmaceuticals, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2249833-A1 | PRODRUGS OF CGRP RECEPTOR ANTAGONIST | Merck Sharp & Dohme Corp. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009100090-A1 | PRODRUGS OF CGRP RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-6774115-B1 | BACTERICIDES | ENANTA PHARMACEUTICALS, INC. | 2004-08-10 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| US-6300360-B1 | FOR THERAPY OF STRESS RELATED DISORDERS SUCH AS POST TRAUMATIC STRESS DISORDER (PTSD) AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION | 2001-10-09 | — | — | US | disclosed |
| US-6063956-A | APPLYING FUNGICIDE OR INSECTICIDE TO THE LOCUS WHERE CONTROL IS DESIRED | ROHM AND HAAS COMPANY (US) | 2000-05-16 | — | — | US | disclosed |
| EP-0432275-B1 | SUBSTITUTED BICYCLOHEPTANDIONE DERIVATIVES | NIPPON SODA CO (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5330888-A | Silver halide emulsion layer containing pyrrolotriazole cyan coupler and lipophilic phenol, sulfur compound or nitrogen compound | FUJI PHOTO FILM CO., LTD. (JP) | 1994-07-19 | — | — | US | disclosed |
| US-5187053-A | Storage stability | FUJI PHOTO FILM CO., LTD. (JP) | 1993-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345689-B2 | Compound and organic light emitting display device | DRD4, NECTIN4, DRD1 | CYP2A6 1614/4885TDP1 1681/4885CYP19A1 2230/4885 |
| US-20180370957-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DISPLAY DEVICE | DRD4, NECTIN4, DRD1 | CYP2A6 1614/4885TDP1 1681/4885CYP19A1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.